Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
Mar 04, 2021
AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th
Feb 24, 2021
AIM ImmunoTech's Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer
Feb 16, 2021
AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy
Feb 10, 2021
AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the Netherlands
Feb 05, 2021
AIM ImmunoTech Completes and Closes ATM Facility; Current Capital Expected to Meet Needs for Current Clinical Trials
Jan 29, 2021
AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen
Jan 15, 2021
AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET
Jan 11, 2021
AIM ImmunoTech Postpones Investor Conference Call. Will Reschedule for a Later Date
Jan 06, 2021
AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue "Long Hauler" Patient Dosed with Ampligen
Dec 24, 2020
AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers
10
11
12
13
14
15
16
17
18
19
20
<<
<
>
>>
Privacy